No abstract

A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens). 2015; 14:81-90. 5. Liu X, Zhang Y, Zheng SY, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017;87:767-774. 6. Zheng SY, Zhang Y, Long T, et al. Short term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight/obese PCOS women. Obes Med. 2017;7:15-20. 7. Fan XX, Yao LY, Hu YJ, et al. Effect study of Exenatide on patients with polycystic ovary syndrome and type 2 diabetes in plateau area [in Chinese].

No abstract

No abstract

No abstract